Operating Income (Loss) in USD of FIBROGEN INC from 2013 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Fibrogen Inc quarterly/annual Operating Income (Loss) history and change rate from 2013 to Q3 2025.
  • Fibrogen Inc Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$5.41M, a 88.7% increase year-over-year.
  • Fibrogen Inc Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$39.5M, a 83.4% increase year-over-year.
  • Fibrogen Inc annual Operating Income (Loss) for 2024 was -$150M, a 53.4% increase from 2023.
  • Fibrogen Inc annual Operating Income (Loss) for 2023 was -$323M, a 7.21% decline from 2022.
  • Fibrogen Inc annual Operating Income (Loss) for 2022 was -$301M, a 4.33% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

FIBROGEN INC Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$39.5M -$5.41M +$42.3M +88.7% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025
Q2 2025 -$81.8M -$12.1M +$34.4M +74% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025
Q1 2025 -$116M -$14.9M +$34.3M +69.7% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025
Q4 2024 -$150M -$7.13M +$88M +92.5% 01 Oct 2024 31 Dec 2024 10-K 17 Mar 2025
Q3 2024 -$238M -$47.7M +$15.8M +24.9% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025
Q2 2024 -$254M -$46.4M +$41.6M +47.3% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025
Q1 2024 -$296M -$49.2M +$26.9M +35.4% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025
Q4 2023 -$323M -$95.1M -$28.9M -43.8% 01 Oct 2023 31 Dec 2023 10-K 17 Mar 2025
Q3 2023 -$294M -$63.5M +$30.2M +32.2% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024
Q2 2023 -$324M -$88M -$9.82M -12.6% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024
Q1 2023 -$314M -$76.1M -$13.1M -20.8% 01 Jan 2023 31 Mar 2023 10-Q 06 May 2024
Q4 2022 -$301M -$66.2M +$69.1M +51.1% 01 Oct 2022 31 Dec 2022 10-K 26 Feb 2024
Q3 2022 -$370M -$93.7M -$145M -284% 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023
Q2 2022 -$225M -$78.2M +$55.6M +41.6% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023
Q1 2022 -$281M -$63M +$7.43M +10.6% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023
Q4 2021 -$289M -$135M -$77.2M -133% 01 Oct 2021 31 Dec 2021 10-K 26 Feb 2024
Q3 2021 -$211M $51M +$18.6M +57.7% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022
Q2 2021 -$230M -$134M -$48.7M -57.2% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022
Q1 2021 -$181M -$70.4M +$10.6M +13.1% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022
Q4 2020 -$192M -$58M +$42.4M +42.3% 01 Oct 2020 31 Dec 2020 10-K 27 Feb 2023
Q3 2020 -$234M $32.3M +$85.2M 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021
Q2 2020 -$320M -$85.1M -$198M -175% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021
Q1 2020 -$122M -$81.1M -$32.2M -66% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021
Q4 2019 -$89.3M -$100M -$120M -604% 01 Oct 2019 31 Dec 2019 10-K/A 04 Mar 2022
Q3 2019 $31M -$52.9M -$10.1M -23.6% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020
Q2 2019 $41.1M $113M +$136M 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020
Q1 2019 -$94.9M -$48.8M -$8.24M -20.3% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020
Q4 2018 -$86.7M $19.9M +$55.5M 01 Oct 2018 31 Dec 2018 10-K 01 Mar 2021
Q3 2018 -$142M -$42.8M -$20M -88.1% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019
Q2 2018 -$122M -$23.2M +$6.9M +22.9% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019
Q1 2018 -$129M -$40.6M -$11.8M -40.9% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019
Q4 2017 -$117M -$35.6M -$7.92M -28.6% 01 Oct 2017 31 Dec 2017 10-K 02 Mar 2020
Q3 2017 -$109M -$22.7M -$637K -2.88% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018
Q2 2017 -$109M -$30.1M -$56.7M -214% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018
Q1 2017 -$52.1M -$28.8M -$2.04M -7.6% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018
Q4 2016 -$50M -$27.7M +$20.8M +42.9% 01 Oct 2016 31 Dec 2016 10-K 27 Feb 2019
Q3 2016 -$70.8M -$22.1M +$21.7M +49.5% 01 Jul 2016 30 Sep 2016 10-Q 08 Nov 2017
Q2 2016 -$92.5M $26.5M -$32.8M -55.3% 01 Apr 2016 30 Jun 2016 10-Q 07 Aug 2017
Q1 2016 -$59.7M -$26.8M +$17.9M +40.1% 01 Jan 2016 31 Mar 2016 10-Q 09 May 2017
Q4 2015 -$77.6M -$48.4M -$473K -0.99% 01 Oct 2015 31 Dec 2015 10-K 27 Feb 2018
Q3 2015 -$77.2M -$43.8M -$6.68M -18% 01 Jul 2015 30 Sep 2015 10-Q 08 Nov 2016
Q2 2015 -$70.5M $59.3M +$10.1M +20.6% 01 Apr 2015 30 Jun 2015 10-Q 08 Aug 2016
Q1 2015 -$80.6M -$44.7M -$30.5M -215% 01 Jan 2015 31 Mar 2015 10-Q 09 May 2016
Q4 2014 -$50.1M -$48M 01 Oct 2014 31 Dec 2014 10-K 01 Mar 2017
Q3 2014 -$37.1M 01 Jul 2014 30 Sep 2014 10-Q 12 Nov 2015
Q2 2014 $49.2M 01 Apr 2014 30 Jun 2014 10-Q 13 Aug 2015
Q1 2014 -$14.2M 01 Jan 2014 31 Mar 2014 10-Q 12 May 2015

FIBROGEN INC Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$150M +$172M +53.4% 01 Jan 2024 31 Dec 2024 10-K 17 Mar 2025
2023 -$323M -$21.7M -7.21% 01 Jan 2023 31 Dec 2023 10-K 17 Mar 2025
2022 -$301M -$12.5M -4.33% 01 Jan 2022 31 Dec 2022 10-K 26 Feb 2024
2021 -$289M -$96.7M -50.4% 01 Jan 2021 31 Dec 2021 10-K 26 Feb 2024
2020 -$192M -$103M -115% 01 Jan 2020 31 Dec 2020 10-K 27 Feb 2023
2019 -$89.3M -$2.62M -3.02% 01 Jan 2019 31 Dec 2019 10-K/A 04 Mar 2022
2018 -$86.7M +$30.6M +26.1% 01 Jan 2018 31 Dec 2018 10-K 01 Mar 2021
2017 -$117M -$67.2M -134% 01 Jan 2017 31 Dec 2017 10-K 02 Mar 2020
2016 -$50M +$27.6M +35.5% 01 Jan 2016 31 Dec 2016 10-K 27 Feb 2019
2015 -$77.6M -$27.5M -54.9% 01 Jan 2015 31 Dec 2015 10-K 27 Feb 2018
2014 -$50.1M -$42.2M -530% 01 Jan 2014 31 Dec 2014 10-K 01 Mar 2017
2013 -$7.95M 01 Jan 2013 31 Dec 2013 10-K 29 Feb 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.